Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 4
2020 5
2021 4
2022 12
2023 12
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Medical Genetics, Genomics and Bioinformatics-2022.
Klimontov VV, Koshechkin KA, Orlova NG, Sekacheva MI, Orlov YL. Klimontov VV, et al. Among authors: sekacheva mi. Int J Mol Sci. 2023 May 18;24(10):8968. doi: 10.3390/ijms24108968. Int J Mol Sci. 2023. PMID: 37240312 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Mercury and cancer: Where are we now after two decades of research?
Skalny AV, Aschner M, Sekacheva MI, Santamaria A, Barbosa F, Ferrer B, Aaseth J, Paoliello MMB, Rocha JBT, Tinkov AA. Skalny AV, et al. Among authors: sekacheva mi. Food Chem Toxicol. 2022 Jun;164:113001. doi: 10.1016/j.fct.2022.113001. Epub 2022 Apr 18. Food Chem Toxicol. 2022. PMID: 35447290 Review.
Clinically relevant fusion oncogenes: detection and practical implications.
Sorokin M, Rabushko E, Rozenberg JM, Mohammad T, Seryakov A, Sekacheva M, Buzdin A. Sorokin M, et al. Among authors: sekacheva m. Ther Adv Med Oncol. 2022 Dec 26;14:17588359221144108. doi: 10.1177/17588359221144108. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36601633 Free PMC article. Review.
Biomedical Applications of Non-Small Cell Lung Cancer Spheroids.
Rozenberg JM, Filkov GI, Trofimenko AV, Karpulevich EA, Parshin VD, Royuk VV, Sekacheva MI, Durymanov MO. Rozenberg JM, et al. Among authors: sekacheva mi. Front Oncol. 2021 Dec 7;11:791069. doi: 10.3389/fonc.2021.791069. eCollection 2021. Front Oncol. 2021. PMID: 34950592 Free PMC article. Review.
RNA sequencing for research and diagnostics in clinical oncology.
Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A. Buzdin A, et al. Among authors: sekacheva m. Semin Cancer Biol. 2020 Feb;60:311-323. doi: 10.1016/j.semcancer.2019.07.010. Epub 2019 Aug 11. Semin Cancer Biol. 2020. PMID: 31412295 Review.
Cytokine Profile in Lung Cancer Patients: Anti-Tumor and Oncogenic Cytokines.
Essogmo FE, Zhilenkova AV, Tchawe YSN, Owoicho AM, Rusanov AS, Boroda A, Pirogova YN, Sangadzhieva ZD, Sanikovich VD, Bagmet NN, Sekacheva MI. Essogmo FE, et al. Among authors: sekacheva mi. Cancers (Basel). 2023 Nov 13;15(22):5383. doi: 10.3390/cancers15225383. Cancers (Basel). 2023. PMID: 38001643 Free PMC article. Review.
Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways.
Zolotovskaia MA, Modestov AA, Suntsova MV, Rachkova AA, Koroleva EV, Poddubskaya EV, Sekacheva MI, Tkachev VS, Garazha AV, Glusker AA, Seryakov AP, Vladimirova US, Rumiantsev PO, Moisseev AA, Zharkov DO, Kuzmin DV, Zhao X, Prassolov VS, Shegay PV, Li X, Steinbichler TB, Kim E, Sorokin MI, Wang Y, Buzdin AA. Zolotovskaia MA, et al. Among authors: sekacheva mi. DNA Repair (Amst). 2023 Mar;123:103448. doi: 10.1016/j.dnarep.2023.103448. Epub 2023 Jan 13. DNA Repair (Amst). 2023. PMID: 36657260
38 results